ACCEPT : une étude conjointe de GA 2LEN et Schering Plough sur l’implémentation des recommandations ARIA

Abstract

GA 2LEN is a European cooperative group for research and standardization of practices in the field of respiratory allergies. At its request, Schering Plough Laboratories accepted to promote two clinical trials – ACCEPT-1 recently published and ACCEPT-2, whose prior investigator is Pr Jean Bousquet – aiming to evaluate, within the ARIA guidelines, the efficacy of desloratadine 5 mg in a single dose per day versus placebo, in treating intermittent and persistent allergic rhinitis. The main results of these trials as well as their consequences on treatment practices are reported herein.